System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 1 citation

PubMed: 40430451 DOI: 10.3390/ph18050630

Effects of Carnosine Supplementation on Cognitive Outcomes in Prediabetes and Well-Controlled Type 2 Diabetes: A Randomised Placebo-Controlled Clinical Trial.

Pharmaceuticals (Basel) 18(5)

Authors: Rohit Hariharan, Aya Mousa, Kirthi Menon, Jack Feehan, Barbara Ukropcová, Jozef Ukropec, Martin Schön, Arshad Majid, Giancarlo Aldini, Maximilian de Courten, James Cameron, Simon M Bell, Barbora de Courten

Affiliations

  • Monash Centre for Health Research Implementation, Faculty of Medicine, Nursing and Health Sciences, Monash University, 43-51 Kanooka Grove, Clayton, VIC 3168, Australia.
  • Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, 246 Clayton Road, Clayton, VIC 3168, Australia.
  • School of Health and Biomedical Sciences, STEM College, RMIT University, 30 Janefield Drive, Bundoora, VIC 3083, Australia.
  • Department of Metabolic Disease Research, Institute of Experimental Endocrinology, Biomedical Research Centre, Slovak Academy of Sciences, Dúbravská Cesta 9, 845 05 Bratislava, Slovakia.
  • Division of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Moorenstraße 5 Universitätsklinikum, 40225 Düsseldorf, Germany.
  • Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Auf'm Hennekamp 65, 40225 Düsseldorf, Germany.
  • German Center for Diabetes Research (DZD), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
  • Sheffield Institute for Translational Neuroscience, School of Medicine and Population Health, University of Sheffield, 385a Glossop Rd, Sheffield S10 2HQ, UK.
  • Department of Pharmaceutical Sciences, University of Milan, Via Luigi Mangiagalli, 25, 20133 Milan, Italy.
  • Institute of Health and Sport, Victoria University, 70/104 Ballarat Rd, Footscray, VIC 3011, Australia.
  • NIHR Sheffield Biomedical Research Centre, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Glossop Rd, Broomhall, Sheffield S10 2JF, UK.
  • Neuroscience Institute, University of Sheffield, Firth Court, 385a Glossop Rd, Broomhall, Sheffield S10 2TN, UK.

Abstract

Background: Trends in global ageing underscore the rising burden of age-related cognitive decline and concomitant cardiometabolic diseases, including type 2 diabetes mellitus (T2DM). Carnosine, a naturally occurring dipeptide with anti-inflammatory, antioxidant and anti-glycating properties, has shown promise in animal models and limited human studies for improving cognitive function, insulin resistance and T2DM, but its therapeutic effects on cognition remain unclear. The aim of this study is to assess the effects of carnosine on cognitive function in individuals with prediabetes or well-controlled T2DM. Methods: This is a secondary analysis of a double-blind randomised controlled trial (RCT), whereby 49 adults with prediabetes or early-stage well-controlled T2DM were randomised to receive 2 g of carnosine or identical placebo daily for 14 weeks. At baseline and follow-up, cognitive function was assessed as a secondary outcome using the Digit-Symbol Substitution Test, Stroop test, Trail Making Tests A & B, and the Cambridge Automated Neuropsychological Test Battery (CANTAB). Results: In total, 42 adults (23 males and 19 females) completed the trial. There were no differences in participant anthropometry or cognitive functioning between carnosine and placebo groups at baseline (all p > 0.1). After the 14-week supplementation period, there were no differences between carnosine and placebo groups in change and follow-up values for any cognitive measures including Stroop, Digit Symbol Substitution Sest, Trail Making A/B or CANTAB (all p > 0.05). Adjustments for baseline cognitive scores, diabetic status, level of education, age or interaction effects with participants' sex did not change the results. Conclusions: Carnosine supplementation did not improve cognitive measures in individuals with prediabetes or T2DM in this study. While larger trials may provide further insights, alternative factors-such as the relatively young and healthy profile of our cohort-may have contributed to the lack of observed effect. Future research should examine individuals with existing cognitive impairment or those at higher risk of cognitive decline to better define the therapeutic potential of carnosine in this context.

MeSH

Diabetes Mellitus, Carnosine, Neuropsychological Tests, Trail Making Test, Cognitive Dysfunction, Prediabetic State, Therapeutics, Cognition, Diabetes Mellitus, Type 2